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1.0 Specific Aims 
The cytomegalovirus (CMV) is capable of causing serious illness and death in 
immunocompromised individuals. The objective of this research is to develop a method of 
detecting antibodies against CMV. This has lead to the development of an Enzyme linked 
Immunosorbent Assay (ELISA) that is capable of detecting CMV or anti-CMV antibodies. The 
process in the development of such an assay involves; 1) the purification of Hyperimmune 
Rabbit Serum containing anti-CMV antibodies, 2) determination of the appropriate 
concentrations necessary to provide a clear and concise response to the test, and 3) testing of 
monoclonal antibodies to determine their specificity towards the cytomegalovirus. 
2.0 Background and Significance 
There are three main classifications of individuals which are affected by the cytomegalovirus: 
Normal, Congenital, and Immunocompromised. In the normal individual, CMV is held in check 
by a well functioning immune system . Clinical manifestations of the virus are in a state of 
latency. Therefore , the normal individual will not experience signs or symptoms of the virus 
unless the immune system becomes compromised. Congenital effects of CMV are seen when a 
fetus is exposed to the virus before the third trimester. Such an exposure has lead to an increase 
in infant mortality. At birth, infants have not yet developed a strong immune system and are 
therefore susceptible to the effects of infection . A CMV infection in the fetus may result in any 




Immunocompromised individuals such as AIDS patients and organ transplant recipients suffer 
from a suppressed immune system. In these individuals CMV can be particularly virulent. Such 
an infection can not only lead to serious illness but also death. There are several complications 
seen with a CMV infection in the immunosuppressed individuals. Conditions which may result 






In a compromised immune system, the cytotoxic T lymphocytes may no longer be capable of 
destroying virus infected cells. Immunotoxins may be capable of carrying out the processes of 
the dysfunctional lymphocytes. A toxin may be targeted to specific cells when attached to 
immunoglobulin G (IgG). This IgG also provides a mode of entry for the immunotoxin to enter 
the cell and effectively eliminate the virus. A combination of immunotoxin and antiviral drug, 
may be a feasible cell-specific approach to the eradication of a viral infection. The antiviral drug 
will hold the virus in check and allow for the immunotoxin to locate and eliminate CMV infected 
cells. It is essential that the antiviral-immunotoxin treatment be specific to cells infected with 
CMV as to not cause further damage and cytotoxicity. 
An Enzyme Linked Immunosorbent Assay (ELISA) will facilitate in the identification of specific 
anti-CMV antibodies. An ELISA is a method of quantitatively measuring the interaction 
between antibody binding to antigen. In this case, it is the interaction between antigens present 
on the surface of CMV with antibodies specific towards the virus. The ELISA is capable of 
detecting either the presence of anti-CMV antibodies or the presence of CMV itself. Antibodies 
are detected by first coating a microplate with CMV and then applying antibodies to each well. 
Those antibodies which are specific to CMV will bind to the surface antigens on the virus. These 
anti-CMV antibodies are then detected through the addition of an enzyme linked antibody which 
will attach directly to the antibody that is attached to CMV. The enzyme is then reacted with a 
substrate and quantitated using a microplate reader. Through a series of washes , the ELISA 
plates can provide accurate data regarding the specificity of the antibodies toward CMV. 
3.0 Purification of Polyclonal Rabbit Serum against MCMV 
Antibody production occurs when an animal (in this case a rabbit) is immunized with antigen. 
The animal will then undergo an antibody response and begin producing antibod y. 
Hyperimmune rabbit serum (HRS) contains several antibodies against various materials. It is 
necessary to purify these antibodies to obtain only those against murine cytomegalovirus 
(MCMV). The process of antibody purification involves several different stages. The following 
steps were conducted to obtain a purified antibody: 1) ammonium sulfate precipitation , 2) 
dialysis to reduce the volume , 3) Sephacryl S200 column chromatography and BCA protein 
assay to determine IgG fraction , and 4) SDS PAGE to assess the purity of the fractions. 
3.1 Ammonium Sulfate Precipitation 
HRS Anti-MCMV (14.0 ml of each 12/31/93 and 3/17/94) was place into a centrifuge 
tube and centrifuged at 2100 rpm for 30 min at 15 °C. The supernatant was then removed 
and saved. The pellet was discarded, as it only contained cell fragments and membranous 
material. 25 ml of supernatant was collected. 20.5 ml Saturated Ammonium Sulfate 
(SAS) , which contained 55 g of Ammonium Sulfate to every 100 ml of deionized water , 
was slowly added to the supernatant to make a 45% volume by volume solution. This 
solution was then allowed to incubate at 4 °C overnight for precipitation . After 
incubation , the suspension was centrifuged at 2000 rpm for 30 min at 15 °C. The 
supernatant was then collected in a separate flask. The pellet was redissolved in a 
phosphate buffer saline (PBS) solution, which contained 8.5 g sodium chloride for every 
1000 ml of deionized water. The buffer was added to make a total volume of 25 ml. 20.5 
ml of SAS solution was again added and centrifuged at 2000 rpm for 30 min at 15 °C. 
After draining the supernatant and suspending the pellet using the same procedure as 
directed above, the solution was once again centrifuged . The supernatant from this final 
centrifugation was collected and the pellet was suspended in PBS to a total volume of 30 
ml. The solution at this point was a semi-clear mixture. 
3.2 Dialysis of Hyperimmune Rabbit Serum 
The dialysis tubing was soaked in deionized waster to saturation. One end of the tubing 
was clamped then filled with deionized water to examine for leakage. The dialysis tubing 
was then filled with the IgG-PBS solution and placed in 1000 ml of 0.85% of NaCl 
solution. The saline solution was changed approximately every 5-10 hrs. during the 
dialysis . After approximately 24 hrs. of dialysis, the NaCl saline solution was drained 
off. Polyethylene glycol was sprinkled over the dialysis tubing until it was covered. This 
compound draws the remaining water out of the tube to concentrate the IgG present. This 
reaction was allowed to proceed until approximately 5 ml oflgG-PBS solution remained . 
The polyethylene glycol was rinsed off using distilled water. The dialysis tubing was 
then placed int 0.85% NaCl solution containing 2% sodium azide which is a 
bacteriostatic. The protein solution was allowed to concentrate to just below 5 ml. 
3.3 Sephacryl S200 Column and BCA Protein Assay 
A 15 mm diameter x 80 mm length column containing Sephacryl S200 Superfine beads 
was used to separate the IgG from other proteins . 
3.3.1 Molecular Weight Markers 
The column, a molecular weight marker mixture was first passed. The following 
table lists the specific markers that were used. 
MARKER MOLECULAR 
WEIGHT 
Blue Dextran 2,000,000 
Beta Amylase 200,000 
Alcohol Dehydrogenase 150,000 
Albumin 66,000 
Carbonic Anhydrase 29,000 
Cytochrome C 12,400 
3.3.2 BCA Protein Assay 
A Bicinchoninic acid (BCA) protein assay was used to determine protein 
concentration in the different fractions from the S200 column. The interaction 
with the BCA molecules and a cuprous ion has a strong absorbance at 562 nm of 
light wavelength. Due to this characteristic , the concentration of protein in each 
fraction can be measured by spectrophotometry . Each of the standards were 
pipetted into labeled test tubes at a volume of 0.1 ml. Two ml of the working 
reagent (containing 50 parts of BCA Reagent A with 1 part of BCA Reagent B) 
was added to each of the test tubes . The test tubes were then allowed to incubate 
at 37 °C for 30 min. The solutions were transferred to a cuvette ant the optical 
density was read at 540 nm in a spectrophotometer. A standard curve was then 
constructed showing the peaks where the molecular weight markers appeared in 
the fractions. The markers appeared in tubes 24-50. The following graph shows 
the peaks that were found. See Appendix 1 for the specific molecular weight 
markers and their optical Density . 
Molecular Weight Markers 
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3.3.3 HRS Sample 
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Five ml of the HRS sample was then added to the Sephacryl S200 column. Based 
on the data obtained from the molecular weight markers, it was speculated that the 
IgG would fall somewhere between fraction tubes 20-48. Fractions were 
collected from the column. A small portion from each tube was diluted to 1: 10 by 
transferring 20 ul of each sample to round bottom 96 well plate and adding 
180 ul of borate buffer (containing 0.015 M sodium borate, 0.15 M NaCl , and 
.02% sodium azide at a pH of 8.5) . IO ul of the diluted solution was then placed 
into a flat bottom 96 well plate and 200 ul of BCA working reagent solution was 
then added to each well. The plate was allowed to incubate at 37 °C and the 
optical density was read in the spectrophotometer at 540 nm. The following graph 
illustrates the concentrations in the fraction tubes at 30 min incubation time. See 
Appendix 2 for complete information on the sample tube and the optical density 
of the HRS. 
HRS BCA Assay 
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3.4 SDS Polyacrylamide Gel Electro_p_horesis 
The polyacrylamide gel electrophoresis (SDS PAGE) is a useful technique in the 
determination of the purity of the fractions obtained from the Sephacryl S200 column. 
By using different molecular weight markers , the location of the bands oflgG will be 
known . This will allow for easy location of the fraction tubes which contain the highest 
concentration oflgG. 
3.4.1 SDS PAGE of HRS 
This SDS PAGE was run using a 10% gel. The procedure was performed as 
described in the BIO-RAD instructions. Two gels were run to test fraction tubes 
24-38. Two types of molecular weight markers were utilized to aid in the 
detection of the fractions containing the highest concentration of IgG. The 
following tables list the markers and their molecular weight. 
Kaleidoscope Standards 
MARKER MOLECULAR COLOR 
WEIGHT 
Myosin 205,000 Blue 
Beta galactosidase 140,000 Magenta 
Bovine serum albumin 83,000 Green 
Carbonic anhydrase 45,000 Violet 
Soybean trypsin inhibitor 32,600 Orange 
Lysozyme 18,000 Red 
Aprotinin 7,500 Blue 
BIO-RAD Standards 
MARKER MOLECULAR WEIGHT 
Myosin 200,000 
Beta galactosidase 116,250 
Phosphor ylase b 97,400 
Bovine Serum Albumin 66,200 
Ovalbumin 42,699 
Carbonic Anhydrase 31,000 
Soybean Trypsin Inhibitor 21,500 
Lysozyme 14,000 
All of the HRS samples were run at a 1: 5 dilution. The gels were set up according 
to the lists below. Reproductions of the SDS PAGE were made and are included 
with the corresponding gel list. 
GEL#l 
1. Kaleidoscope Standards 
2. BIO-RAD Standards 
3. HRS S200 Fraction #24 
4. HRS S200 Fraction #25 
5. HRS S200 Fraction #26 
6. HRS S200 Fraction #27 
7. HRS S200 Fraction #28 
8. HRS S200 Fraction #29 
9. HRS S200 Fraction #30 
10. HRS S200 Fraction #31 
GEL#2 
1. Kaleidoscope Standards 
2. BIO-RAD Standards 
3. HRS S200 Fraction #32 
4. HRS S200 Fraction #33 
5. HRS S200 Fraction #33 
6. HRS S200 Fraction #34 
7. HRS S200 Fraction #35 
8. HRS S200 Fraction #36 
9. HRS S200 Fraction #37 
10. HRS S200 Fraction #38 
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From the gels collected, it was determined that the fractions containing the highest 
concentration oflgG were 29-34. These fractions were pooled into a single 
sample to be used in the development of an enzyme linked immunosorbent assay. 
4.0 Enzyme Linked Immunosorbent Assay (ELISA) 
The objective of this research was to design a method which will rapidly detect and quantify anti-
CMV antibodies. The Enzyme Linked Immunosorbent Assay (ELISA) provides a rapid and 
reliable means of accomplishing this goal. This CMV specific method was developed as 
described in the protocol termed "Antibody-Sandwich ELISA for Soluble Antigens". 
4.1 HRS Coated ELISA Plate 
Initially positive and negative controls were used to determine the appropriate 
concentration of the coating antibody, the cytomegalovirus , the enzyme labeled detection 
antibody , and to determine the sensitivity of the assay. The positive virus sample used 
was partially purified MCMV #3 from 11/23/94. The negative virus sample was 
uninfected c127i Cells #6 from 11/23/94. The ELISA plates were coated with various 
concentrations of the purified HRS which had been pooled from the Sephacryl Superfine 
column S200 fractions . The plates were washed with distilled water. Blocking buffer 
(BB) was then placed on each plate to bind any free areas on the surface. This will 










application of reagents, the plates were washed and blocked with blocking buffer. 
Several dilutions of the MCMV samples were made and allowed to react with the HRS. 
The application of MCMV required the use of a Hyperimrnune Mouse Serum (HMS) 
antibody . The mouse antibody recognizes the MCMV and binds to the antigens. A 
Normal Mouse Serum (NMS) was also utilized on several of the rows as a control to 
ensure that proper binding. A control will also ensure that a positive test will indeed 
indicate the presence of anti-MCMV antibodies. 
To quantify the amount of antibody binding to the virus, it is necessary to have a visual 
chemical reaction. This demand is met through the application of an alkaline phosphatase 
labeled goat anti-mouse antibody. The antibody must be directed against mouse 
antibodies in order that binding will occur with the HMS. Following binding of the 
enzyme labeled antibody , p-nitrophenyl phosphate (NPP) substrate solution is applied . It 
is this solution that is hydrolyzed by the alkaline phosphatase . Hydrolysis results in a 
yellow color that can be quantified using a microplate reader at a wavelength of 405 nm . 
The amount of color present is directl y related to the amount of HRS bound to the 
MCMV. The following table represents a plate indicating the optimal concentrations of 
each reagent which provided a clear and concise determination of the presence of MCMV 
specific antibodies. 








I :4000 HMS 
1:100 1:200 I :400 1:800 I: 1600 1:100 1:200 1 :400 1 :800 1: 1600 BB 
MCMV #3 11/23/94 cl27i Cells #6 11/23/94 
In the plate depicted above , HRS was the coating antibody. HRS was placed on the 
specified rows at the concentrations indicated. The plate was divided in half and MCMV 
was added to the left half of the plate at the indicated concentrations while the control 
c 127i cells were added to the right half at the indicated concentrations. HMS and NMS 
were added to the indicated rows at a 1: 1000 dilution . On the rows marked with "None ", 
no antibody was added . This was a control to ensure that an accurate response to the 
ELISA would be evident. The AP- goat anti-mouse was added to the entire plate at a 
uniform dilution of 1: 1000. These specific concentrations resulted in clear and concise 
quantification of the presence of anti-MCMV antibody. The following figure illustrates 
the interaction of the various antibodies and the virus . 
Hyperimmune Mouse 
Serwn(HMS) 









To develop a rapid method of such quantification the first step of the ELIS A previousl y 
developed was eliminated. Rather that coating the plate with the HRS antibody , that 
plate was coated directly with MCMV . The various dilutions of MCMV were extended 
to determine the lowest concentration needed to obtain accurate results . The NMS and 
HMS were again applied to the virus coated plates . AP-goat anti-mouse antibodies was 
used as the enzyme linked antibody and NPP as the substrate solution . The following 

















HMS 1 :5000 
HMS 1 :5000 
BB 1:100 1:500 1:1000 1:5000 1:10,000 1:100 1:500 1:1000 1:5000 1:10,000 BB 
MCMV #3 11/23/94 cl 27i Cells #6 11/23/94 
In the plate depicted above , the MCMV and cl 27i cells were used to coat the plate . The 
uninfected cells were used as a control measure. The MCMV and c 127i cells were 
applied in the concentrations indicated. On the rows marked with None, no antibody was 
added . This again was used as as a control to ensure the an accurate response to the 
ELISA would be evident. The AP-goat anti-mouse antibody was added to the entire plate 
at as a uniform dilution of 1: 1000. These specific concentrations resulted in clear and 
concise quantification of the presence of anti-MCMV antibody. In eliminating the 
binding of HRS to the plate before the virus could be bound , this ELISA was noticeably 
shorter then the first protocol. The following figure shows the difference between the 









4.3 Monoclonal Antibody ELISA Titer Values 
Using the second ELISA developed in which MCMV was used to coat the plates , various 
monoclonal antibodies available in the laboratory were tested to determine their virus 
titer. Some of the antibodies are known to react with MCMV, however, the extent of the 
antibody - antigen interaction has yet to be determined. In order to determine the virus 
ELISA titer it was necessary to alter the concentration of MCMV in coating the plates . 
The titer values were obtained via end point dilution. The dilutions of MCMV coating 
are listed on the following figure. This diagram shows as a 96 well ELISA plate with the 
virus concentrations listed at the bottom . 
"b 6 6 6 6 6 6 6 6 a 6 c3 
eO O O O O O O O O O O 0 
cO O O O O O O O O O O 0 
oO O O O O O O O O O O 0 
£000000000000 
rOOOOOOOOOOOO 
60 0 0 0 0 0 0 0 0 0 0 0 
"9 9 9 9 9 9 9 9 9 9 
BB 1:488 1 :6488. 1 :1 '.aES 1 :1.6£6 * 1 :2.6£7 
1 :1688 1 :2.5E4 1. .1 ES 1 :6.5E6 BB 
The protocol listed in the second ELISA developed using MCMV as the coating agent 
was strictly followed. The following table indicates the ELISA plate number, the specific 
monoclonal antibodies on each plate, their isotype, and the ELISA titer. 
ELISA Plate# Monoclonal Ab Isotype ELISA Titer (um/ml) 
la A8 .9.18 IgG2a 6400 
2a Al4.H2.G7 IgG2a 26214400 
2b A24.4.9 IgG2b 26214400 
3a A24.5.4 IgG3 400 
3b A25 .C3 .B5 IgG2a 6553600 
4a A35 .5.H4 IgG2a 6553600 
4b C2.89.E7 IgG2b 25600 
5a C3.83.F5 IgG2b 409600 
5b C8.7.6 IgG2 b 25600 
6a C34.18 .F6 lgG2a 6553600 
6b C35. l .4a lgG3 409600 
7a D5.F I0 .88 IgG2a 262 14400 
7b D18 .13.F l I lgG2a 26214400 
8a D28.2. I0 lgG3 6400 
8b D30.83 .F6 lgG2a 1600 
9a D32.3. HI0 IgG2b 25600 
9b El2 .CIO .H7 IgG2a 25600 
!0a E28.Hl.Dl I IgG2a 6400 
10b G3.6.2 IgG3 6400 
11 a L8.Bl.Cl2 IgG3 25600 
lib L.12.A .12.F4 IgG2b 409600 
12a Ll8.Dl 1.86 IgGI 6553600 
12b 828 .D3 .C9 100 
13a PC4.9 .A6 6400 
13b HG88554 Mixture 6400 
This table indicates the monoclonal antibodies which have a high titer towards the 
cytomegalovirus . The stronger the affinity of the antibody toward the virus , the higher 
the titer value will be. In this study, the titer background was 0.05. The cutoff was 2 
times the background resulting in 0.10. The strongest reading obtained was 0.8 which is 
16 times the background level. This ensures that the titer values obtained reflect the 
specificity of the monoclonal antibody towards CMV. The titer values for monoclonal 
antibodies are large due to the previous purification. Purification removed obsolete 
proteins and other antibodies from ascites fluid which may hinder the binding ability of 
antibodies specific towards CMV. The data obtained shows that some monoclonal 
antibodies have a strong affinity for CMV while others only bind weakly. It was 







The ELISA developed is effective in detecting antibodies specific to CMV. Based on the results 
obtained, this ELISA method of testing for antibodi es towards the cytomegalovirus is both 
accurate and precise . 
The future direction of this ELISA method is extremely promising. It can further be used in 
clinical testing . It has the potential to determine the presence of CMV in humans . Particles may 
be extracted from blood and used to coat an ELISA plate . Monoclonal antibodies with a high 
specificity towards the cytomegalovirus , such as those previously mentioned in this study, may 
then be applied. Following the procedure indicated , the presence of virus may then be 
determined . 
This ELISA method will also facilitate in the construction CMV specific immunotoxins. The 
ELISA will determine those antibodies which are specific to CMV . These antibodies can then be 
used to construct immunotoxins which will target only those cells which have been infected. 
This will allow for the immun e system to detect infected cells and destroy them. 
APPENDIX 1 
Molecular Weight Markers 



































Hyerpimmune Rabbit Serum 
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